Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis

  • In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo1
  • Treatment with remibrutinib led to significant improvement in symptom control, as early as Week 2 and sustained up to Week 121
  • Remibrutinib was well-tolerated and demonstrated a favorable safety profile with rates of overall adverse events comparable to placebo and balanced liver
/by
Mentoring matters: how we grow together at Novartis

Mentoring matters: how we grow together at Novartis
kabagke1

/by
Mentoring matters: how we grow together at Novartis

Mentoring matters: how we grow together at Novartis
kabagke1

/by
Belonging here: How Novartis helped me come out as a transgender woman

Belonging here: How Novartis helped me come out as a transgender woman
kabagke1

/by
Belonging here: How Novartis helped me come out as a transgender woman

Belonging here: How Novartis helped me come out as a transgender woman
kabagke1

/by
How I found my true purpose at Novartis

How I found my true purpose at Novartis
kabagke1

/by
How I found my true purpose at Novartis

How I found my true purpose at Novartis
kabagke1

/by
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis

  • FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21
  • As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2
  • HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide3
/by
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis

  • FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21
  • As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2
  • HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide3
/by
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by